Trials / Not Yet Recruiting
Not Yet RecruitingNCT06394713
A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
A Phase 1b/2 Trial to Evaluate the Efficacy and Safety of QLF31907 (PD-L1/4-1BB Bi-specific Antibody) Combination Therapy in Patients With Advanced Malignant Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLF31907 | intravenous administration, once every 3 weeks |
| DRUG | Irinotecan | intravenous administration, 125 mg/m2, d1 and d8, every 3 weeks |
| DRUG | Docetaxel | intravenous administration, 75mg/m2, d1, every 3 weeks |
Timeline
- Start date
- 2024-06-15
- Primary completion
- 2025-06-15
- Completion
- 2026-12-15
- First posted
- 2024-05-01
- Last updated
- 2024-05-01
Source: ClinicalTrials.gov record NCT06394713. Inclusion in this directory is not an endorsement.